An observational study in Peripheral Artery Disease, Restenosis of Peripheral Vascular Stent and Restenosis, Vascular Graft, sponsored by Ryazan State Medical University. Completed. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-05-03.
Sponsored by Ryazan State Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is aimed at evaluating the role of the activity of the key hemostatic parameters of endothelial dysfunction (nitric oxide II (NO) metabolites, plasmin activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), coagulation factor VIII (FVIII), soluble endothelial protein C receptors (sEPCR)) in the development of disease progression, thrombotic complications and restenosis in subjects with atherosclerotic peripheral artery disease.
The study will involve patients with atherosclerotic peripheral artery disease (Rutherford category 3-5). The subjects are to be divided into three groups:
Group A: patients who undergo bypass surgery with a synthetic graft on aorto-iliac or femoro-popliteal segment; Group B: patients who undergo endovascular balloon angioplasty and stenting on aorto-iliac or femoro-popliteal segment; Group C: patients who undergo standard of care conservative treatment.
Decisions on revascularization or conservative treatment alone is to be made by a team of vascular specialists in accordance with the severity of the disease, previous treatment, anatomy, possible need for repeat procedures in the future, and patient's preferences.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
This study's enrollment of 167 is below the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Browse Peripheral Arterial Disease studies →Ryazan State Medical University is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A prospective study is aimed at enrolling 200 patients with atherosclerotic peripheral arterial disease, Rutherford category 3-5. The patients with PAD are scheduled to undergo either open or endovascular reconstructive procedures on aorto-iliac and femoro-popliteal segment or conservative treatment alone. The subjects of similar age, sex, and ethnicity are to be divided into three groups, respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with atherosclerotic peripheral artery disease (PAD) who undergo standard of care conservative treatment according to the current PAD guidelines.
Subjects with atherosclerotic peripheral artery disease who undergo an open bypass grafting with synthetic prosthesis in aorto-iliac or femoro-popliteal position
Procedure: an arterial reconstructive procedure
Subjects with atherosclerotic peripheral artery disease who undergo endovascular balloon angioplasty and stenting with bare-metal stents in aorto-iliac or femoro-popliteal position
Procedure: an arterial reconstructive procedure
thrombosis
incidence of thrombotic complications in the target arterial segment
Time frame: 1 year
restenosis
incidence of restenosis in the target arterial segment
Time frame: 1 year
progression of atherosclerosis
detection of newly formed or progressing peripheral atherosclerotic lesions
Time frame: 1 year
limb salvage rate
limb salvage rate in the target extremity
Time frame: 1 year
acute myocardial infarction
incidence of acute myocardial infarction
Time frame: 1 year
mortality rate
overall mortality rate
Time frame: 1 year
No study locations are listed for this record.
Plan to share: Undecided — Basic demographic data, including sex, age, and ethnicity are to be shared if allowed by the privacy policy.
Ran from Jan 2017 to primary completion in Feb 2023, 73 months.
Of 138 non-industry observational studies under Peripheral Arterial Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's 73 months is above that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ryazan State Medical University